INTRODUCTION
Differentiation of self-renewing adult human epithelial stem cells into rapidly proliferating progenitor cells is a conserved early event in human tissue development and homeostasis. Systematic and coordinated regulation by master transcription factors, noncoding RNA-mediated networks, or the establishment of progressive epigenetic marks have been proposed as likely regulatory mechanisms (Hanna et al., 2010) . Identification of control mechanisms will enable the basic understanding of epithelial dynamics and could identify common perturbations leading to the disruption of epithelial homeostasis in cancers. We have investigated the nature of stem cell regulation during early human epithelial differentiation using patient-derived prostate epithelium as our primary experimental tool. In human prostate, stem-like cells (SCs) of a basal phenotype and their early differentiated progeny (transit amplifying [TA] and committed basal cells [CB] ) can be reproducibly enriched from patient-derived benign and malignant tissues by selecting for differential CD133, CD44, and a 2 b 1 integrin expression (Collins et al., 2005; Richardson et al., 2004) . Transcriptional profiling of prostate SCs and CBs identified consistent gene expression changes associated with differentiation and carcinogenesis (Birnie et al., 2008) . We have now investigated the expression pattern and the regulation of genes that are differentially expressed in the SC and CB populations, supplemented by a largescale analysis of published transcriptomic experiments, to identify shared signaling pathways that regulate general epithelial differentiation.
RESULTS AND DISCUSSION

Identification of Genes Coregulated during Prostate Stem Cell Differentiation
Coexpression analysis was performed on differentially expressed Affymetrix probes between SC and CB from the Birnie et al. (2008) data set ( Figure 1A) to identify functionally related and coregulated genes without introducing observer or selection bias (Lee et al., 2004) . Probes with high pairwise correlation (Pearson's correlation coefficient, R R 0.8 or R % À0.8) were clustered into four distinct groups (A-D) ( Figures 1B and 1C ). All the correlations (above the threshold) were positive and no significant connections between probes within the four groups were seen. Analysis of independent published microarrays (Shepherd et al., 2008) showed similar changes in the expression of group A-D genes during prostate stem cell differentiation (data not shown). Gene ontology (GO) analysis further revealed that the genes in each group are functionally related. Groups B, C, and D genes were principally enriched for differentiation-associated processes ( Figure 1B ). Group C genes exhibited a distinct enrichment for genes constituting the ''epidermal differentiation complex'' (SPRR and S100 families) (Benitah, 2012; Mischke et al., 1996) . Interactive Pathway Analysis (IPA) (Kececioglu and Kim, 2006 ) of group C further revealed a significant enrichment for genes having critical functions in generic ''tissue developmental events'' (p < 0.01) and genes known to be coregulated by strong differentiation-associated regulators such as retinoic acid (RA) (p = 2.94 3 10 À13 ) and ROCK2 (p = 9.89 3 10 À8 ). IPA analysis did not provide convincing evidence for differentiation-associated coregulation of group B. These results framed the hypothesis that group C genes could be coexpressed in a variety of human tissues and could play a broader functional role in differentiation.
Gene Sets Coexpressed during Prostate Stem Cell Differentiation Are Coexpressed in the Majority of Human Cell Types
A compendium data set of 24,536 human Affymetrix microarrays from 806 experiments, representing at least 150 distinct human cell types, was generated to test whether group A-D genes are coexpressed across multiple cell types, pathologies, and treatments (Figures 2A and 2B ). This data set is the largest singly normalized human microarray data set we are aware of. Unlike most others (Rhodes et al., 2007; Seita et al., 2012) , it is not restricted to any particular sample type, tissue type, or pathology. Assessment of the raw microarray data for technical and experimental accuracies resulted in the removal of 507 corrupted or experimentally faulty experiments (Supplemental Experimental Procedures available online). Overall, the final data set yielded about 1.2 billion expression correlations between genes. We confirmed the quality and utility of this data set for gene variation analysis by performing GO analysis on the 100 least variable probes, which identified the most invariable genes (by coefficient of variation after normalization) in human cells, e.g., ribosomal genes and control genes for quantitative RT-PCR (qRT-PCR)/western blot normalization (Table S1 ). The data set can also be used to construct background interaction modeling to identify interactions representing normal physiology or common occurrences. Overlaying this background network on a transcriptomic data set of interest facilitates removal of background interactions, leaving behind experimentspecific biological behavior. However, the more restricted analysis in this study clearly demonstrated that group A-D genes were significantly coexpressed ( Figure 2C 
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Group C Genes Are Likely Markers or Mediators of Stem Cell Differentiation
While group B genes showed stronger coexpression in the compendium data set and exhibited interesting GO term enrichment, group C genes provided more compelling evidence for their coregulatory and differentiation-associated properties. IPA and literature analyses (62 out of 80 genes in group C had at least one PubMed publication linking them to differentiation) strongly implied differentiation-specific coregulation of group C. We selected LCN2, CEACAM6, S100P, and TMPRSS2 as group C representative genes to assess group C coregulation, on the basis of strong evidence for their role in SC differentiation or prostate epithelial dynamics and their tight coexpression pattern. Microarray expression of the candidate genes ( Figure 2D ) was confirmed by both qRT-PCR ( Figure S1 ) and western blot analysis ( Figure 2E ). In a wide variety of mammalian tissues, low expression of these genes has been shown to denote SC properties (He et al., 2009; Polson et al., 2013; Zheng et al., 2009 ). Furthermore, TMPRSS2 and S100P are considered to be classical androgen responsive genes in terminally differentiated cells, which can promote oncogenesis in prostate epithelium (Averboukh et al., 1996; Lin et al., 1999) , and S100P has also been shown to be responsible for PC3 cell differentiation into luminal-like cells (Floryk and Thompson, 2008) . Similar functions therefore translate into tight coexpression of the genes within the compendium data set, where S100P had a more similar expression pattern to that of LCN2 and CEA-CAM6 than any other gene in the human genome (Figure 2F) . TMPRSS2 was also significantly coexpressed with these three genes ( Figure 2F ). Such functional attributes and bioinformatic analyses both indicated that LCN2, CEACAM6, S100P, and TMPRSS2 (and group C) are coregulated during prostate SC differentiation.
Retinoic Acid Regulates Group C Genes Inducing Early Prostate Stem Cell Differentiation
Multiple bioinformatic tools and a published literature evaluation were utilized to identify potential regulators of group C genes ( Figure 3A) . The analyses identified RA as the most likely regulator of gene expression because (1) IPA analysis suggested that RA can regulate group C; (2) ENCODE chromatin immunoprecipitation (ChIP) analysis of HepG2 cells also showed a significant enrichment for retinoid X receptor a (RXRA) binding sites on the promoters of group C; (3) LCN2, CEACAM6, S100P, and TMPRSS2 have putative RAR and RXR binding sites within their promoters (data not shown); (4) , 1995) , the outcome of RA signaling manipulation in adult human prostate epithelial differentiation is unknown. The case for transcription-factor-mediated regulation of group C is also enhanced by the lack of evidence for a common regulatory mechanism in terms of microRNA, histone acetylation, and DNA methylation even for the group C candidate genes (data not shown).
To test whether RA is indeed a principal regulator of prostate epithelial SC differentiation, benign and malignant patient-derived prostate epithelial cells (PPECs) were treated with 100 nM all-trans retinoic acid (at-RA). The group C candidate genes showed a 4-to 60-fold increase in expression within 72 hr ( Figures 3C-3F ), accompanied by a modest but statistically insignificant decrease in cell number (not shown). The rapid increase in TMPRSS2 expression levels (6 hr posttreatment) suggested that this gene could be a direct target of RA, whereas the other three genes responded more slowly and are more likely, on a kinetic basis, to be RA-''responsive'' genes. A similar trend (E) Western blot analysis of LCN2, CEACAM6, and S100P expression. Representative image, n = 6 each for benign prostatic hyperplasia (BPH) and treatment-naïve prostate cancer (PCa) (biological replicates). (F) Rainbow contour graphs for the correlation of coexpression for TMPRSS2, CEACAM6, LCN2, and S100P with each other in compendium data set. Values at the top of each square indicate correlation coefficient. All values are significant with p < 0.05. All boxplots show minimum, 25%, median, 75%, and maximum. See also Figure S1 and Table S1 . 
was also noted in at-RA-treated prostate SCs ( Figure 3G ). The RA responsiveness of these genes has been shown in other experimental models; for example, LCN2, S100P, and CEACAM6 were upregulated in sebaceous cells after 13-cis-RA treatment (Nelson et al., 2008) . Analysis of publically available microarray data ( Figure 3H) confirmed that group C genes are also upregulated in response to RA treatment in four different cell types, including human embryonic SCs. Taken together, these findings demonstrate that the majority of group C genes are RA-responsive genes. Next, we assessed whether RA treatment alone, while modulating group C expression, could also induce early prostate SC differentiation. Treatment of PPECs with 100 nM at-RA for 72 hr induced (1) suppression of colony-forming efficiency by approximately 60% (Figure 3I ), indicating a decrease in self-renewing cells; (2) a >50% decrease in the expression of the progenitor cell marker CD49f (Figures 3J and 3K ) and a 12% decrease in CD49b expression (data not shown); (3) a decrease in CK5 (basal CK) expression with a concomitant increase in luminal CK18 expression ( Figures 3L-3N) ; (4) a decrease in NF-kB1 and ID2 expression levels, which promote a SC phenotype; and (5) increased expression of the differentiation-associated genes WNT5a and PAP ( Figure 3O) (Birnie et al., 2008) . Classical prostate luminal differentiation markers, such as AR, PSA, and NKX3.1, remained unaltered after at-RA treatment ( Figure 3O ). A similar increase in endogenous RA levels in prostate cancer patients after treatment with liarozole also resulted in a minimal increase in luminal differentiation (Denis et al., 1998) . Two human clinical trials also showed only a modest increase in the expression of PSA and PAP (in only about 30% of patients). These findings indicated that at-RA treatment can induce differentiation of prostate SCs to CBs, which are primed for luminal differentiation (as suggested by the increase in PAP and CK18 levels) but confirm that RA alone cannot force luminal differentiation. In this scenario, overexpression of all the candidate group C genes in luminal cells (Oudes et al., 2006) prompted us to assess the existence of additional regulators of group C genes in prostate epithelial differentiation.
Androgens Can Regulate Group C during Terminal Human Prostate Epithelial Differentiation
The majority of group C genes were indeed overexpressed in patient-derived luminal compared to basal cells (Oudes et al., 2006) (Figure 4A and S3) , implying that another transcription factor, distinct from RA, may regulate group C to sustain and promote gene expression during luminal differentiation. Because systemic and niche-driven AR-mediated signaling is the main regulator of luminal differentiation in prostate and is capable of inducing luminal differentiation, even in 3D culture, with an obligatory contribution from stroma (Lang et al., 2006) , we assessed the responsiveness of group C to AR stimulation in publically available microarray data. Group C was consistently upregulated upon AR stimulation in multiple prostate cell line models ( Figure 4B ), confirming that group C genes can respond to a tissue-specific transcription factor (like AR) in cells primed for terminal differentiation. However, this presented a conundrum about the ''principal'' regulator of group C genes during prostate epithelial differentiation. We therefore treated prostate cells, possessing a distinct basal or luminal phenotype, with at-RA or R1881 (an AR agonist). In cells with a basal phenotype, at-RA, but not R1881, upregulated TMPRSS2 expression (up to 80-fold), whereas TMPRSS2 (C-F) qRT-PCR analysis of CEACAM6, LCN2, S100P, and TMPRSS2 expression after 100 nM at-RA treatment of PPECs; n = 5 for BPH (3) and PCa (2) (biological replicates). (G) qRT-PCR analysis of CEACAM6, LCN2, S100P, and TMPRSS2 expression after 100 nM at-RA treatment of SCs; mean values shown for BPH (five) and PCa (four) (biological replicates). Figures 4C and S4A) . Similar observations were also made for CEACAM6 and S100P ( Figures S4B and S4C ). Inhibition of AR signaling has also been shown to inhibit the expression of these genes in LNCaP cells ( Figure 4D ; Averboukh et al., 1996) . This experimental evidence indicated that RA and AR act in a cell-type-dependent manner to coregulate group C, providing a fuller explanation for the observed expression changes in TMPRSS2 (strongly considered solely as an androgen-regulated gene) in androgen-independent basal cells (Polson et al., 2013) .
This study provides direct evidence for the mechanistic role of RA during adult prostate SC differentiation, where ALDH hi cells with SC properties in prostate (van den Hoogen et al., 2010) can serve as a potential source of RA. Prostate epithelial SCs with no detectable AR expression respond to RA stimulation through a set of 80 genes, transforming SCs into basal cells committed to terminal differentiation (luminal). The genes can then preferentially respond to androgens during terminal differentiation. The change in regulatory preference could be due to multiple factors, such as weakening of a RA morphogenetic gradient from the basal to the luminal layer (Shimozono et al., 2013) , loss of contact with the basement membrane and niche (Lang et al., 2006) , chromatin modifications induced by RA (Kashyap et al., 2013) , or changes in the expression of independent differentiation-associated chromatin modifying genes (e.g., group B genes). When the distinction of a basal-luminal cell type is not clear, as in intermediate prostate epithelial cells (van Leenders et al., 2000) and cell lines, competition between RA-and ARmediated signaling may result in competitive inhibition of one of the two response pathways (Young et al., 1994) . The reduced RA content of prostate cancer tissue compared to normal tissue (Pasquali et al., 1996) , where AR-responsive terminally differentiated cells predominate ($99% of total cells), suggests that the tissue strives to minimize AR-RA antagonism by downregulating the less efficient signaling mechanism. Cooperation/interference between RA and AR signaling (Rivera-Gonzalez et al., 2012) may therefore regulate prostate epithelial differentiation and dynamics through a similar set of genes. In mammary epithelial development, RA also regulates early differentiation, whereas a tissue-specific transcription factor (estrogen receptor) can then promote terminal epithelial differentiation (Förster et al., 2002; Seewaldt et al., 1997) . Our data now reveal the existence of similar two-step regulation of differentiation in other epithelial tissues.
In terms of prostate cancer management, our data strongly suggest that RA treatment should lock prostate cancer stem cells into an AR-independent committed basal cell phenotype, which will not be affected by prevailing androgen-blocking therapy (Rane et al., 2012) . Our data link two of the most conserved prostate epithelial differentiation-regulatory pathways to a shared gene set, providing a mechanistic insight into adult human epithelial dynamics.
EXPERIMENTAL PROCEDURES
Establishment of Primary Cultures
Patient tissue material was obtained following written consent and full ethical approval (NHS Research Governance Framework: NRES reference number 07/H1304/121). Cultures were established from patient-derived cancer (all Gleason 7) and benign prostatic hyperplasia biopsy specimens and SC, TA, and CB cells were selected as described previously (Collins et al., 2005) at passage 2.
Construction and Analysis of Compendium Data Set
Transcriptomic data were normalized by RMA and annotated. Row-wise correlation analysis was used to yield a matrix of correlations between all probes. See the Supplemental Experimental Procedures for additional details.
Expression Analysis
qRT-PCR analysis was performed as described previously (Oldridge et al., 2013) . Details of TaqMan probes and antibodies used for western blot, fluorescence-activated cell sorting, and immunofluorescence analyses are in the Supplemental Experimental Procedures.
Colony-Forming Efficiency
A total of 200 cells were plated in each well of a six-well collagencoated plate with 500 ml of irradiated mouse fibroblasts. Colonies generated by individual cells were counted after 12-18 days.
Statistical Analysis
Experiments were carried out with at least three different samples (each in triplicate) representing at least two different experiments. Error bars shown are the SD. The significance was determined by Student's two-tailed t test. Wilcoxon rank sum test was used to calculate significance of cytokeratin immunofluorescence. 
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